Neurochem Announces Launch of European Phase III Clinical Trial on Alzhemed? For Treatment of Alzheimer's Disease
The multi-centre, randomized, double-blind, placebo-controlled and parallel designed European Phase III clinical trial will investigate the safety and efficacy of Alzhemed? in treating AD, with some 930 mild-to- moderate AD patients taking part in the trial.
In July, Neurochem completed the enrolment of 1052 mild-to-moderate AD patients for its North American Phase III clinical trial on Alzhemed?.
About Alzhemed?
Azhemed? is an orally administered, small organic molecule specifically designed to modify the course of AD by binding to soluble amyloid (B) (A(B)) protein and keeping it in a non-fibrillar form. As reported previously, results of the Phase II trial demonstrated that there were no apparent safety findings of concern in patients treated with Alzhemed? and that the investigational product candidate was well tolerated in individuals with mild-to-moderate AD.
Source:YAHOO
